Compare Celgen Biopharmaceuticals vs PhaseBio Pharmaceuticals
Customers evaluate the quality of Celgen Biopharmaceuticals's products using the following success metrics.
Overview
Celgen Biopharmaceuticals is based in China
Shanghai Celgen Biopharmaceutical is a bio-similar biopharmaceuticals drugs developer and manufacture in China mainly focused on Inflammation, Oncology and Metabolic Disease. Celgen's main product is a Monoclonal Antibody (MAB) called Etanercept a Generic version of Amgen's Enbrel used for the treatment of inflammatory conditions such as Rheumatoid arthritis, Juvenile rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Plaque psoriasis.
PhaseBio Pharmaceuticals is 22 yrs old and is based in United States.
PhaseBio Pharmaceuticals (NASDAQ: PHAS) develops drugs to treat diabetes and cardiovascular dysfunction in patients suffering from rare diseases. The Company's discovery platform technology uses recombinant ELP biopolymers to control the half-life, bioavailability, and physical characteristics of molecules for ease of administration. It was founded in 2002 and is based in Malvern, Pennsylvania.
Demo Video
Leadership
Jonathan P Mow (Chief Executive Officer)
Funding
Investors
China-Israel Value Capital
Johnson & Johnson Innovation, New Enterprise Associates
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Celgen Biopharmaceuticals has not claimed their profile.
Work for Celgen Biopharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Celgen Biopharmaceuticals?
Claim your profile now.
Information not available because PhaseBio Pharmaceuticals has not claimed their profile.
Work for PhaseBio Pharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for PhaseBio Pharmaceuticals?
Claim your profile now.